Second European Medicines Agency workshop on neurodegenerative diseases: focus on dementia

This workshop is involving a panel of European experts actively involved in clinical and non-clinical research into dementia. The United States Food and Drug Administration is contributing to the debate on the current regulatory requirements in terms of development of new medicines for dementia.The workshop is expected to allow the participants to convey their respective views and identify a common ground of enrichment between academia, patients, healthcare professionals, industry and regulators.The elements originating during the discussion will not constitute a formal specific advice on